Key facts
- Coave Therapeutics’s last known valuation is $38.2M (Dec 2022).
- It has raised $80.8M; the latest was Later Stage VC ($33.3M) in Jan 2025.
- Notable investors include Bpifrance, Novo Holdings, UI Investissement, The Invus Group, GO Capital — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Coave Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Coave Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Coave Therapeutics
Developer of genetic medicine technologies intended to address neurodegenerative diseases through targeted therapies. The company's platform is useful for delivering low doses of therapeutic genes like GBA1 and TFEB directly to the central nervous system, enhancing autophagy and lysosomal function, enabling researchers and healthcare providers to develop effective treatments for conditions such as ALS and other related disorders while improving patient outcomes and quality of life.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2014
- Employees
- 34
- Website
- coavetx.com/
- Ownership
- Privately Held (backing)
Coave Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Coave Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Coave Therapeutics in its N-PORT filings yet. We sweep new filings monthly.